Developing a wearable device for continuous cerebral blood flow monitoring, positioned around brain hemodynamics, performance, and broader brain health applications.
Funding, launches and regulatory moves across the neurotech startup map.
Subscribed. Check your inbox to confirm.
Temple
news and updates
21 Oct 2026: Founder Deepinder Goyal announced that pre-orders for Temple Batch 01 open on 1 November 2026. Units are made to order and delivered within three months of purchase, and pricing has not been announced. In August, Goyal described the device as less than half its earlier size.
Jun 2026: Temple introduced Entropy, a 1 to 250 score of metabolic and sympathetic demand, updated every second. The company reports a 0.93 correlation with metabolic-cart measurements across more than 100 cardio sessions, without published methods.
27 Feb 2026: Temple raised $54M at a reported $190M post-money valuation in a friends-and-family round. Goyal led the round, followed by Steadview Capital, with Peak XV Partners, InfoEdge Ventures and Dharana Capital also investing.
•
Neurofounders Insights
$ Funding -
Seed
MODALITY
Others
FORM FACTOR
Patch
INTERFACE DEPTH
Non-invasive
INDICATION
Wellness
TARGET USER
Consumers
REGULATORY STAGE
Non-medical
Temple is positioned as a consumer brain-hemodynamics wearable, using cerebral blood-flow monitoring for performance and general brain health. Its wellness framing and unusual physiological angle distinguish it from EEG-heavy consumer neurotech.
%20copy.jpg)
.svg)
